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1. Introduction
   Dendrimer represents a novel type of polymeric material. 
It is also known as starburst[1] or cascade[2] or molecular 
trees[3] or arborols, or polymers. They attract the increasing 
attention of all because of their unique structure, high 
degree of control over molecular weight and the shape 
that has led to the synthesis of unimolecular micelles[4-7]. 
Considering the use of dendrimers for drug delivery, it 
is necessary that they are nontoxic and biocompatible. 
However, it has been demonstrated that widely used 
dendrimers, such as PAMAM and poly (propyleneimine) 
(PPI) dendrimers bearing primary amino group termini, 
are quite cytotoxic, and also these dendrimers were 
cleared rapidly from the circulation when administered 
intravenously[8]. Poly ethylene glycol (PEG) is typically a 
clear, colorless odorless substance that is soluble in water, 
stable to heat, inert to many chemical agents, that does not 
hydrolyze or deteriorate, and is generally non-toxic, PEG 
is considered to be biocompatible, which is to say that PEG 
is capable of coexistence with living tissue or organisms 
without causing harm, as reviewed earlier[9]. It has been 
shown that covalent attachment of poly (ethylene glycol) 
to proteins decreases their immunogenicity and increases 
their circulation time. Moreover, a number of studies have 
demonstrated that poly (ethylene glycol) chains grafted to 
surface of polymer micelles and liposomes suppress their 
interaction with plasma proteins and cells and prolong their 
blood elimination half-life. On the basis of these findings, 
it seems that dendrimers covered with poly (ethylene glycol) 
grafts are attractive compounds as drug carriers in in vivo. 
The purpose of the present experimental investigations 
was to assess the antileukemic activity of an Prednisolone 
loaded PEGylated Polypropyleneimine (PPI) dendrimer in 
comparison with free Prednisolone.
Objective: To developing and exploring the use of PEGylated poly (propylene imine) dendritic 
architecture for the delivery of an anti leukemic activity of Prednisolone. Methods: For this 
study, PEGylated poly (propylene imine) dendritic architecture was synthesized and loaded with 
Prednisolone and targeted to the ascetic form of myelogenous leukemia k-562 cellines in hybrid 
mice BDF1, was used as tumor model. The antileukemic activity was assessed by use of the 
criterion T/C %, where T was the mean survival time (MST, days) of the drug treated mice, bearing 
k-562 leukemia  and C - the mean survival time (MST, days) of untreated control animals, bearing 
the same leukemia cellines. Results: An antileukemic activity of the studied Prednisolone loaded 
PEGylated Polypropyleneimine (PPI) dendrimer was found to have increasing the mean survival 
time of the k-562 myelogenous leukemia cellines bearing BDF1 mice. The criterion “increase 
of life span” (ILS%) reached maximally 270.1% for the drug loaded dendrimer. Conclusion: The 
studied dendrimer with Prednisolone showed lower toxicity with improved antileukemic activity 
in comparison with free Prednisolone. The further experiments in this field are in progress, 
aiming to design better dendritic formulations, with potential clinical use
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2. Materials and methods
2.1. Materials
   PEG4000, Reney Nickel (Sigma, Germany), Raney 
Nickel (Merck, India), Triethylamine, Ethylenediamine, 
Acrylonitrile (CDH, India), N, N dicyclohexyl carbodiimide 
(DCC), Cellulose dialysis bag (MWCO 12-14 Kda, Himedia, 
India), Prednisolone was a benevolent gift from Shasun 
Pharmaceuticals, Chennai, India.
2.2. Methods
2.2.1. Synthesis of 5.0G PPI dendrimer
   5.0G PPI dendrimer was synthesized by following the 
procedure reported by (De Brabender-Van Den Berg and 
Meijer) using EDA as initiator core. Briefly, ethylenediamine 
(EDA) was used as initiator core and acrylonitrile was 
added to it in a double Michael addition-reaction method 
to produce half generation (-CN terminated), followed by 
heterogeneous hydrogenation using Reney Nickel as catalyst 
to produce full generation (-NH2) dendrimers. The reaction 
sequence was repeated cyclically to produce PPI dendrimers 
up to fifth generation (PPI-5.0G) as shown in Figure 1.
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Figure 1. Schematic diagram for synthesis of PPI-5G dendrimer.
2.2.2. Synthesis of PEGylated 5.0G PPI Dendrimers
   To a solution of 5G EDA-PPI dendrimer (0.01 mmol) in 
dimethyl sulfoxide (DMSO) (10 mL), PEG 2000 (0.32 mmol) 
in DMSO (10 mL) and N, N dicyclohexyl carbodiimide (DCC) 
(0.32 mmol) in DMSO (10 mL) were added and the solution 
was stirred for 5 d at room temperature. The product was 
precipitated by addition of water, filtered and dialyzed 
(MWCO 12-14 Kda, Himedia, India) against double distilled 
water for 24 h to remove free PEG 2000, DCC and partially 
PEGylated dendrimers followed by lyophilization (Heto 
drywinner, Germany).The preparation of PEGylated 5.0 G PPI 
dendrimers was shown in Figure 2.
2.3. Drug loading in formulation
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   The known molar concentrations of EDA-PPI dendrimer 
and PEGylated 5.0G dendrimers were dissolved separately 
in methanol and mixed with methanolic solution of 
Prednisolone (100 mol). The mixed solutions were incubated 
with slow magnetic stirring (50 rpm) using teflon beads 
for 24 h. These solutions were twice dialyzed in cellulose 
dialysis bag (MWCO 1000 Da Sigma, Germany) against 
double distilled water under sink conditions for 10 min to 
remove free drug from the formulations, which was then 
estimated spectrophotometrically (λmax 248 nm) (UV-1601, 
Shimadzu, Japan) to determine indirectly the amount of drug 
loaded within the system. The dialyzed formulations were 
lyophilized and used for further characterization.
2.4. Antileukemic activity
   The in vivo studies were performed in male hybrid BDF1 
mice. The antileukemic activity was studied on ascitic form 
of myelogenous k-562 leukemia, with transplantation dose 
of 1×105 tumor cells/mouse, on day 0, intraperitoneally 
(i.p.). Prednisolone and Prednisolone loaded PEGylated 
Polypropyleneimine (PPI) dendrimer were introduced 
intraperitoneally, once a day, on day 1, day 4 and day 8 
after the tumor transplant. The antileukemic activity was 
assessed by use of the criterion T/C %, where T was the mean 
survival time (MST, days) of the drug treated mice, bearing 
k-562 leukemia  and C - the mean survival time (MST, days) 
of untreated control animals, bearing the same leukemia 
cellines[10].
2.5. Statistical analysis 
   The activity was assessed by use of the criterion T/C%, 
where T was the mean survival time (MST, days) of the 
drug treated mice, bearing k-562 myelogenous leukemia 
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and C - the mean survival time (MST, days) of untreated 
control animals, bearing the same leukemia. T/C%> 125% is 
considered as significant.
3. Result
   The polypropyleneimine dendrimer was synthesized 
by using ethylenediamine as a core. The synthesized 
dendrimer were further PEGylated with PEG4000. The 
PEGylated dendrimer is used as carrier system, in which 
Prednisolone was loaded and drug entrapment efficiency 
was calculated as (81.2±0.03). The antileukemic activity was 
assessed by use of the criterion T/C%. The results obtained 
from the effect of Prednisolone and its Prednisolone loaded 
PEGylated Polypropyleneimine (PPI) dendrimer on BDF1 
hybrid mice-bearing K-562 leukemia are shown on the 
Table 1. According to these results, the free Prednisolone 
exhibited a pronounced and dose-related antileukemic 
activity on mice-bearing K-562 leukemia. An increase 
of the free Prednisolone dose over 0.25 mg/kg 伊3, i. p., 
caused an increase in its acute toxicity. This fact was 
registered by the progressive decrease in the ratio T/C (treated/
control). The dose of the free Prednisolone of 1.5 mg/kg伊3, 
i. p., was toxic (T/C% < 125%). The Prednisolone loaded 
PEGylated Polypropyleneimine (PPI) dendrimer exhibited 
an antileukemic activity against acute lymphocytic K-562 
in BDF1 mice, in four of the used doses from 0.5 mg/kg伊
3 to 8.0 mg/kg伊3, i. p., with T/C% varying between 195.1% 
and 270.1%. The experimental results on activity of the 
Prednisolone loaded PEGylated Polypropyleneimine 
(PPI) dendrimer showed that an increase in dose levels of 
equivalent to the free drug led to an increase in the ratio T/
C, indicating lower toxicity. The dose of 8.0 mg/kg伊3, i. p., 
was not toxic (T/C% = 270.1%).
Table 1. 
Antileukemic activity of free prednisolone and prednisolone loaded PEGylated PPI 
dendrimer on BDF1 hybrid mice-bearing K-563 leukemia.
Drug and formulation Dose (mg/kg) 伊3, i.p MST ( in days) T/C (%)
Prednisolone 0.25 19.4 179.6
0.5 17.3 166.3
1.0 14.8 142.3
1.5 12.5 120.1
Prednisolone loaded 
PEGylated PPI 
dendrimer
0.5 20.3 195.1
1.0 21.6 207.6
2.0 23.2 223.0
4.0 26.7 256.7
8.0 28.1 270.1
Untreated control 0 10.8
MST - mean survival time (days); T - survival time of treated mice (days); C - survival 
time of control mice (days); Significant antileukemic effect at T/C% > 125% was accepted. 
*Toxic dose at T/C% < 125%.
4. Discussion 
   The antileukemic activity of the Prednisolone loaded 
PEGylated dendrimers are shown more significant 
improvement in mean survival time of cancer affected 
mice than the free Prednisolone, that was favorable by 
clinical point of view. The chemical and pharmacological 
investigations in this field are in progress, aiming to analyse 
the results and trying to design better formulation of selected 
antitumor drugs with dendrimers, for potential clinical use. 
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